{"id":2785,"date":"2021-05-25T08:30:00","date_gmt":"2021-05-25T08:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/stort-intresse-for-xvivos-europeiska-hjartstudie\/"},"modified":"2021-05-25T08:30:00","modified_gmt":"2021-05-25T08:30:00","slug":"stort-intresse-for-xvivos-europeiska-hjartstudie","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/stort-intresse-for-xvivos-europeiska-hjartstudie\/","title":{"rendered":"Stort intresse f\u00f6r XVIVO:s europeiska hj\u00e4rtstudie"},"content":{"rendered":"<div class=\"mfn-body\">\n<p>Den europeiska multicenterstudie som unders\u00f6ker XVIVO:s hj\u00e4rtpreservationsteknologi vid hj\u00e4rttransplantation forts\u00e4tter att inkludera patienter. I dagsl\u00e4get har fyra viktiga europeiska hj\u00e4rttransplantationscenter i Sverige, Belgien, Frankrike och Spanien inkluderat ett <strong>tjugotal<\/strong> <strong>patienter<\/strong> i studien. Ytterligare tre center i Tyskland respektive Italien f\u00f6rv\u00e4ntas \u00f6ppna f\u00f6r inklusion inom de kommande m\u00e5naderna.\u00a0<\/p>\n<p>D\u00e5 ett flertal nya sjukhus har efterfr\u00e5gat m\u00f6jlighet till att delta i studien har XVIVO nu beslutat att <strong>addera ytterligare<\/strong> <strong>fyra<\/strong> framst\u00e5ende europeiska center. Detta st\u00e4rker m\u00f6jligheten att h\u00e5lla ett h\u00f6gt inklusionstempo men \u00e4ven sprida teknologin och den kliniska erfarenheten av metoden.<\/p>\n<p>Den f\u00f6rsta patienten i Europa transplanterades i december 2020 och totalt kommer studien att inkludera 202 patienter. Sammantaget kommer XVIVO:s hj\u00e4rtpreservationsteknologi anv\u00e4ndas i tre multicenterstudier i Europa, USA och Australien. Studierna kommer ligga till grund f\u00f6r ans\u00f6kan om regulatoriskt godk\u00e4nnande av produkterna p\u00e5 alla stora transplantationsmarknader.<\/p>\n<p>P\u00e5 <strong>ISHLT<\/strong>s (International Society of Heart and Lung Transplantations) \u00e5rliga konferens i slutet av april, v\u00e4rldens dominerande m\u00f6te f\u00f6r forskning inom hj\u00e4rttransplantation, presenterades eller omn\u00e4mndes XVIVO:s hj\u00e4rtpresentationsteknologi i flera sammanhang. Bland annat presenterade en ledande forskargrupp inom hj\u00e4rtpreservation resultat fr\u00e5n studier d\u00e4r XVIVOs hj\u00e4rtpreservationsteknologi anv\u00e4nts f\u00f6r preservation av hj\u00e4rtat under 8 timmar utanf\u00f6r kroppen. Efter hj\u00e4rttransplantation \u00f6verlevde <strong>100 procent<\/strong> av de transplanterade f\u00f6rs\u00f6ksdjuren medan kontrollgruppen, d\u00e4r hj\u00e4rtat f\u00f6rvarades med konventionell metod, enbart hade 71 procent \u00f6verlevnad efter transplantation.<\/p>\n<p>\u201dVi kan konstatera att intresset f\u00f6r XVIVO:s hj\u00e4rtpreservationsteknologi \u00e4r mycket stort. Det \u00e4r s\u00e4rskilt gl\u00e4djande att flera framst\u00e5ende europeiska transplantationssjukhus aktivt kontaktat XVIVO och uttryckt \u00f6nskem\u00e5l att inom ramen f\u00f6r v\u00e5r kliniska studie f\u00e5 anv\u00e4nda v\u00e5r teknologi. Detta \u00e4r en mycket stark indikation p\u00e5 den stora potential som finns f\u00f6r metoden och vi ser mycket fram emot att kommersialisera v\u00e5r teknologi s\u00e5 att m\u00e5nga fler hj\u00e4rtan kan transplanteras\u201d s\u00e4ger Dag Andersson, Verkst\u00e4llande direkt\u00f6r p\u00e5 XVIVO.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r ytterligare information, v\u00e4nligen kontakta:<\/strong><\/p>\n<hr\/>\n<p>Dag Andersson, VD, +46 31-788 21 50,\u00a0<a href=\"mailto:dag.andersson@xvivoperfusion.com\" target=\"_blank\" rel=\"nofollow noopener\">dag.andersson@xvivoperfusion.com<\/a><br \/>Kristoffer\u00a0Nordstr\u00f6m,\u00a0CFO, +46 73-519 21 64,\u00a0<a href=\"mailto:kristoffer.nordstrom@xvivoperfusion.com\" target=\"_blank\" rel=\"nofollow noopener\">kristoffer.nordstrom@xvivoperfusion.com<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about\">\n<p><strong class=\"mfn-heading-1\">Om oss<\/strong><\/p>\n<hr\/>\n<p>XVIVO grundades 1998 och \u00e4r ett medicintekniskt f\u00f6retag dedikerat till att f\u00f6rl\u00e4nga livet f\u00f6r donerade organ s\u00e5 att transplantationsteam runt om i v\u00e4rlden kan r\u00e4dda fler liv. V\u00e5ra l\u00f6sningar g\u00f6r det m\u00f6jligt f\u00f6r ledande kliniker och forskare att t\u00e4nja p\u00e5 gr\u00e4nserna f\u00f6r transplantationsmedicin.\u00a0XVIVO har sitt huvudkontor i G\u00f6teborg och har kontor och forskningsanl\u00e4ggningar p\u00e5 tv\u00e5 kontinenter. Bolaget \u00e4r noterat p\u00e5 Nasdaq Stockholm\u00a0och handlas under symbolen XVIVO. Mer information finns att l\u00e4sa p\u00e5 hemsidan www.xvivogroup.com\/us<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/75d61d37-a76e-462e-91e4-999bc918f383\/stort-intresse-for-xvivo-s-europeiska-hjartstudie.pdf\" target=\"_blank\" rel=\"nofollow noopener\">Stort intresse f\u00f6r XVIVO:s europeiska hj\u00e4rtstudie<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Den europeiska multicenterstudie som unders\u00f6ker XVIVO:s hj\u00e4rtpreservationsteknologi vid hj\u00e4rttransplantation forts\u00e4tter att inkludera patienter. I dagsl\u00e4get har fyra viktiga europeiska hj\u00e4rttransplantationscenter&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-2785","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Stort intresse f\u00f6r XVIVO:s europeiska hj\u00e4rtstudie - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/stort-intresse-for-xvivos-europeiska-hjartstudie\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stort intresse f\u00f6r XVIVO:s europeiska hj\u00e4rtstudie - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Den europeiska multicenterstudie som unders\u00f6ker XVIVO:s hj\u00e4rtpreservationsteknologi vid hj\u00e4rttransplantation forts\u00e4tter att inkludera patienter. I dagsl\u00e4get har fyra viktiga europeiska hj\u00e4rttransplantationscenter...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/stort-intresse-for-xvivos-europeiska-hjartstudie\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/stort-intresse-for-xvivos-europeiska-hjartstudie\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/stort-intresse-for-xvivos-europeiska-hjartstudie\\\/\",\"name\":\"Stort intresse f\u00f6r XVIVO:s europeiska hj\u00e4rtstudie - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2021-05-25T08:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/stort-intresse-for-xvivos-europeiska-hjartstudie\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/stort-intresse-for-xvivos-europeiska-hjartstudie\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/stort-intresse-for-xvivos-europeiska-hjartstudie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Stort intresse f\u00f6r XVIVO:s europeiska hj\u00e4rtstudie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Stort intresse f\u00f6r XVIVO:s europeiska hj\u00e4rtstudie - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/stort-intresse-for-xvivos-europeiska-hjartstudie\/","og_locale":"en_US","og_type":"article","og_title":"Stort intresse f\u00f6r XVIVO:s europeiska hj\u00e4rtstudie - XVIVO","og_description":"Den europeiska multicenterstudie som unders\u00f6ker XVIVO:s hj\u00e4rtpreservationsteknologi vid hj\u00e4rttransplantation forts\u00e4tter att inkludera patienter. I dagsl\u00e4get har fyra viktiga europeiska hj\u00e4rttransplantationscenter...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/stort-intresse-for-xvivos-europeiska-hjartstudie\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/stort-intresse-for-xvivos-europeiska-hjartstudie\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/stort-intresse-for-xvivos-europeiska-hjartstudie\/","name":"Stort intresse f\u00f6r XVIVO:s europeiska hj\u00e4rtstudie - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2021-05-25T08:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/stort-intresse-for-xvivos-europeiska-hjartstudie\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/stort-intresse-for-xvivos-europeiska-hjartstudie\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/stort-intresse-for-xvivos-europeiska-hjartstudie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Stort intresse f\u00f6r XVIVO:s europeiska hj\u00e4rtstudie"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}